Startup & VC
Beeline Medicines $300M Series A—From Stealth
Boston-based autoimmune and inflammation therapy maker Beeline Medicines exits stealth with $300 million Series A led by Bain Capital.
Primary sources · 1
Boston-based autoimmune and inflammation therapy maker Beeline Medicines exits stealth with $300 million Series A led by Bain Capital.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.